Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
6,140
Employees6,140
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
6,140
Employees6,140

NTRA Key Statistics

Market cap
27.69B
Market cap27.69B
Price-Earnings ratio
-131.93
Price-Earnings ratio-131.93
Dividend yield
Dividend yield
Average volume
1.34M
Average volume1.34M
High today
$201.29
High today$201.29
Low today
$194.14
Low today$194.14
Open price
$200.49
Open price$200.49
Volume
523.73K
Volume523.73K
52 Week high
$256.36
52 Week high$256.36
52 Week low
$125.38
52 Week low$125.38

Stock Snapshot

As of today, Natera(NTRA) shares are valued at $195.38. The company's market cap stands at 27.69B, with a P/E ratio of -131.93.

On 2026-03-20, Natera(NTRA) stock moved within a range of $194.14 to $201.29. With shares now at $195.38, the stock is trading +0.6% above its intraday low and -2.9% below the session's peak.

Trading volume for Natera(NTRA) stock has reached 523.73K, versus its average volume of 1.34M.

The stock's 52-week range extends from a low of $125.38 to a high of $256.36.

The stock's 52-week range extends from a low of $125.38 to a high of $256.36.

NTRA News

Simply Wall St 13h
Does Natera’s Expanded Genomics Suite Quietly Redefine Its Long-Term Competitive Moat?

Natera recently reported peer-reviewed data underscoring the clinical utility of its Signatera ctDNA assay in anal squamous cell carcinoma and locally advanced...

Does Natera’s Expanded Genomics Suite Quietly Redefine Its Long-Term Competitive Moat?
Simply Wall St 3d
Assessing Natera Valuation After New Signatera Data And Zenith Genomics Launch

Advertisement Why Natera Stock Is Back in Focus Natera (NTRA) is back on many investors’ radars after two fresh peer-reviewed studies on its Signatera cancer...

Assessing Natera Valuation After New Signatera Data And Zenith Genomics Launch
TipRanks 4d
Natera announces publications on clinical utility of Signatera

Natera (NTRA) announced two peer-reviewed publications highlighting the clinical utility of Signatera, its personalized, tumor-informed circulating tumor DNA as...

Analyst ratings

91%

of 22 ratings
Buy
90.9%
Hold
9.1%
Sell
0%

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.